DNAzymes and their therapeutic possibilities.
Our increasing understanding of the regulatory mechanisms involved in the pathogenesis of disease is opening up opportunities for therapeutic intervention. To tackle the unmet disease burden, the last decade has seen the emergence of gene-targeting small-molecule nucleic acid-based strategies, such as antisense oligodeoxynucleotides, ribozymes, small interfering RNA and DNAzymes. DNAzymes represent promising candidates for drug therapy in a wide range of diseases, such as cancer and cardiovascular disorders. This brief review will discuss recent developments in DNAzymes and their therapeutic potential.
Chan
C W S
CW
Centre for Vascular Research, University of New South Wales, Sydney, New South Wales, Australia.
Khachigian
L M
LM
D000818:Animals; D003141:Communicable Diseases / Q000628:therapy; D021881:DNA, Catalytic / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007249:Inflammation / Q000628:therapy; D009369:Neoplasms / Q000098:blood supply / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000628:therapy; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000235:genetics; D051381:Rats; D013379:Substrate Specificity; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D023041:Xenograft Model Antitumor Assays
D021881:DNA, Catalytic; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha